Current advances in tumor proteomics and candidate biomarkers for hepatic cancer

Expert Review of Proteomics

Volumn 6, Issue 5, 2009, Pages 551-561

  Peng, Xin Qing ^b   Wang, Fei ^a   Geng, Xin ^a   Zhang, Wei Ming ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

Candidate biomarker; Epigenetics; Hepatocellular carcinoma; Peptidome; Tumor diagnosis; Tumor proteomics

Indexed keywords

GLYCOPROTEIN; ONCOPROTEIN; PROTEOME; TUMOR MARKER;

BIOINFORMATICS; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER SCREENING; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENOMICS; HUMAN; LASER CAPTURE MICRODISSECTION; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; ONCOGENE; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350435889     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.72     Document Type: Review

References (52)

1. Li Y, Geng X, Zhang W. Application of proteomics to the study of hepatocellular carcinoma and some related diseases. Chin. J. Clin. Oncol. 2(6), 903-906 (2005).
2. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 405(6788), 837-846 (2000).
3. Alessandro R, Fontana S, Kohn E et al. Proteomic strategies and their application in cancer research. Tumori 91(6), 447-455 (2005). (Pubitemid 43251112)
4. Xu X, Jiang Y, Shi Q. Tumor proteomics: the past, present and future. Chin. J. Cancer 27(10), 1009-1017 (2008).
5. Koomen JM, Haura EB, Bepler G et al. Proteomic contributions to personalized cancer care. Mol. Cell. Proteomics 7, 1780-1794 (2008).
6. Lutz1 AM, Willmann JK , Frank V et al. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med. 5(8), 1287-1297 (2008).
7. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 452(7187), 571-579 (2008).
8. Dalton WS, Friend SH. Cancer biomarkers - an invitation to the table. Science 312(5777), 1165-1168 (2006).
9. Hye-Jin Sung, Je-Yoel Cho. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 41(9), 615-625 (2008).
10. Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
11. Kondo T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Reports 41(9), 626-634 (2008).
12. Sawyers CL. The cancer biomarker problem. Nature 452(7187), 548-1452 (2008).
13. Minagawa H, Honda M, Miyazaki K et al. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 366(1), 186-192 (2008). (Pubitemid 350297227)
14. Ardekani AM, Akhondi MM, Sadeghi MR. Application of genomic and proteomic technologies to early detection of cancer. Arch. Iran. Med. 11(4), 427-434 (2008).
15. Lueking A, Cahill DJ, Mullner S. Protein biochips: a new and versatile platform technology for molecular medicine. Drug Discov. Today 10,789-794 (2005). (Pubitemid 40744923)
16. Geng X, Wang F, Li YG et al. SELDI-TOF MS ProteinChip technology for screening of serum markers of HBV-induced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26(4), 505-508 (2007). (Pubitemid 351157867)
17. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116(1), 26-30 (2006). •• The low-molecular-weight peptidome is an important source of low-abundance peptide biomarkers.
18. Hall JA, Brown R, Paul J. An exploration into study design for biomarker identification: issue and recommendations. Cancer Genomics Proteomics 4(3), 111-119 (2007).
19. Ransohoff DF. The process to discover and develop biomarkers for cancer: a work in progress. J. Natl Cancer. Inst. 100(20), 1419-1420 (2008).
20. Pepe MS, Feng Z, Janes H et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 100(20), 1432-1438 (2008).
21. Wang J et al. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma. Chin. Med. J. 118(15), 1278-1286 (2005). (Pubitemid 41150352)
22. Bottoni P, Giardina B, Vitali A et al. A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. Biochim. Biophys. Acta 1794, 615-626 (2009).
23. Minagawa H, Honda M, Miyazaki K et al. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 366(1), 186-192 (2008). (Pubitemid 350297227)
24. Hyoung-Joo Lee, Min-Jeong Kang, Eun-Young Lee et al. Application of a peptide-based PF2D platform for quantitative proteomics in disease biomarker discovery. Proteomics 8, 3371-3381 (2008).
25. Tang HY, Nadeem AK, Echan LA et al. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 5, 3329-3342 (2005). • Novel strategy, termed protein array pixelation, consists of three sequential high-resolution protein fractionation methods.
26. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
27. Zinkin NT. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res. 14(2), 470-477 (2008).
28. Wang JX, Zhang B, Yu JK et al. Application of serum protein fingerprinting coupled with artifitial neural network model in diagnostic of hepatocellular carcinoma. Chin. Med. J. 118(15), 1278-1286 (2005). (Pubitemid 41150352)
29. Feng JT, Liu YK, Song HY et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5, 4581-4588 (2005).
30. Liang RC, Neo JC, Lo SL et al. Proteome database of hepatocellular carcinoma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771(1-2), 303-328 (2002).
31. Aebersold R. A stress test for mass spectrometry-based proteomics. Nat. Methods 6, 411-412 (2009).
32. Veenstra TD, Conrads TP , Hood BL et al. Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics 4, 409-418 (2005).
33. Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 3, 399-409 (2004). (Pubitemid 38702092)
34. Keshishian H, Addona T, Burgess M et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229 (2007). • Methods provide a solid basis for developing quantitative mass spectrometry-based assays of low-level proteins for routine measurement of plasma proteins in the low range.
35. Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int. Rev. Immunol. 26(3-4), 223-247 (2007).
36. Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin. Liver Dis. 26(4), 373-384 (2006).
37. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J. Hepatol. 44, 798-805 (2006).
38. Chignard N, Shang S, Wang H et al. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastroenterology 130(7), 2010-2022 (2006). (Pubitemid 43816962)
39. Jia HL, Ye QH, Qin LX et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res. 13(4), 1133-1139 (2007).
40. Block TM, Comunale MA, Lowman M et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. PNAS 102 (3), 779-784 (2005). •• Identification of several glycoproteins with altered glycosylation as a function of cancer was investigated. (Pubitemid 40282742)
41. Chaerkady R, Harsha HC, Nalli A et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J. Proteome Res. 7(10), 4289-4298 (2008).
42. Ressom HW, Varghese RS, Goldman L et al. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J. Proteome Res. 7(2), 603-610 (2008). (Pubitemid 351294022)
43. He QY, Zhu R, Lei T et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J. Cell. Biochem. 103, 740-752 (2008). (Pubitemid 351240611)
44. Feng Y, Tian ZM, Wan MX et al. Protein profile of human hepatocarcinoma cell line SMMC-7721: identification and functional analysis. World J. Gastroenterol. 13(18), 2608-2614 (2007). (Pubitemid 46938833)
45. Cui JF, Liu YK, Zhou HJ et al. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J. Gastroenterol. 14(8), 1257-1262 (2008).
46. Zhang JZ, Li D, Zheng YH et al. Proteomic profiling of hepatitis b virus-related hepatocellular carcinoma in china: a SELDI-TOF-MS study. Int. J. Clin. Exp. Pathol. 1, 352-361 (2008).
47. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 6(3), 241-247 (2007). (Pubitemid 46925243)
48. Sun W, Xing BC, SunY et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis. Mol. Cell. Proteomics 6, 1798 - 1808 (2007).
49. Forner A, Rodríguez de Lope C, Reig M et al. Early diagnosis of primary liver cancer: imaging versus genetics. Rev. Esp. Enferm. Dig. 100(7), 423-429 (2008).
50. Tommaso LD, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45, 725-734 (2007). (Pubitemid 46450624)
51. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery, and validation: the long, and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-983 (2006). (Pubitemid 44215392)
52. 2DE Protein Database of the Liver Cancer Cell Line http://proteome.btc. nus.edu.sg/hccm